| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5614713 | Journal of Cardiology | 2017 | 5 Pages |
Abstract
Warfarin use significantly increased the risk of serious bleeding, in contrast, CB-A did not place the patients at an increased risk of complications under a DOAC treatment. There were no significant differences regarding preventing embolic events among the DOAC drugs.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Kaoru MD, Tomofumi MD, FACC, Hideshi MD, Naohiko MD, Mitsumi MD, Manabu MD, Hidetoshi MD, Mitsutoshi MD, Tsukasa MD, Yasuteru MD, Tetsuo MD, Kenzo MD,